Novo Nordisk A/S (NVO) Shares Bought by Janus Henderson Group PLC

Janus Henderson Group PLC raised its stake in Novo Nordisk A/S (NYSE:NVO) by 11.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 247,811 shares of the company’s stock after buying an additional 25,382 shares during the period. Janus Henderson Group PLC’s holdings in Novo Nordisk A/S were worth $12,963,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Boston Partners acquired a new position in Novo Nordisk A/S during the 4th quarter worth $99,963,000. Fisher Asset Management LLC raised its stake in Novo Nordisk A/S by 2.9% in the fourth quarter. Fisher Asset Management LLC now owns 14,202,935 shares of the company’s stock valued at $654,329,000 after purchasing an additional 405,531 shares in the last quarter. Avalon Advisors LLC raised its stake in Novo Nordisk A/S by 494.7% in the fourth quarter. Avalon Advisors LLC now owns 422,932 shares of the company’s stock valued at $19,484,000 after purchasing an additional 351,810 shares in the last quarter. Two Sigma Advisers LP raised its stake in Novo Nordisk A/S by 897.5% in the fourth quarter. Two Sigma Advisers LP now owns 278,300 shares of the company’s stock valued at $12,821,000 after purchasing an additional 250,400 shares in the last quarter. Finally, CIBC Asset Management Inc acquired a new position in Novo Nordisk A/S in the fourth quarter valued at about $11,418,000. 7.04% of the stock is owned by institutional investors.

Shares of NYSE NVO opened at $46.94 on Thursday. The company has a debt-to-equity ratio of 0.07, a current ratio of 0.96 and a quick ratio of 0.66. The stock has a market cap of $115.75 billion, a price-to-earnings ratio of 18.63, a price-to-earnings-growth ratio of 2.12 and a beta of 0.56. Novo Nordisk A/S has a 12 month low of $41.23 and a 12 month high of $52.83.

A number of research firms recently commented on NVO. Zacks Investment Research downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Thursday, January 24th. Pareto Securities downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, April 30th. Handelsbanken downgraded Novo Nordisk A/S from a “buy” rating to an “accumulate” rating and set a $48.61 price target for the company. in a research note on Monday, February 4th. Morgan Stanley initiated coverage on Novo Nordisk A/S in a research note on Friday, February 1st. They set an “equal weight” rating for the company. Finally, Credit Suisse Group raised Novo Nordisk A/S from a “neutral” rating to an “outperform” rating in a research note on Monday, April 29th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Novo Nordisk A/S has an average rating of “Hold” and a consensus target price of $52.31.

WARNING: This report was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.com-unik.info/2019/05/16/novo-nordisk-a-s-nvo-shares-bought-by-janus-henderson-group-plc.html.

Novo Nordisk A/S Profile

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

See Also: What is Compound Interest?

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit